Two centuries. Countless innovations. One vision.
Takeda’s LIVTENCITYTM (maribavir) Approved by U.S. FDA as the First and Only Treatment for People Ages 12 and Older with Post-Transplant Cytomegalovirus (CMV), Refractory (With or Without Genotypic Resistance) to Conventional Antiviral Therapies
Takeda Applied for Selection of “Prime Market”, Filed Corporate Governance Report with Tokyo Stock Exchange (TSE) in Line with Revised Corporate Governance Code and Published Corporate Governance related Documents on its website
Takeda Announces Acquisition of Own Shares
Takeda Delivers Strong H1 FY2021 Results; Further Growth Momentum Expected Through Fiscal Year-End Driven by 14 Global Brands
Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic γδT Cell Therapies Addressing Solid Tumors
SEE ALL NEWS AND RELEASES >
・For Shire news releases, click here
Luck is not a strategy: The world needs to start preparing now for the next pandemic
The COVID-19 Mental Burden on Working Mothers
Takeda Neuroscience at the Annual Meeting of the American Academy of Neurology (AAN) 2021
Takeda Breaks Ground on Commercial Cell Therapy Manufacturing Facility in Lexington, Massachusetts
Spotlight Malawi: Many Paths Towards Universal Health Coverage and a Strong Health Workforce
SEE ALL FEATURED TOPICS ARTICLES >
With this new original series featured in Asahi Shimbun Globe, President & CEO Christophe Weber gives his unique perspective on what he has learned from his upbringing in France and his international career.
For media inquiries or reporter requests for more information, contact our Corporate Communications via Media_Relations@takeda.com. If you generally would like to contact us, please visit Contact Us.
Copyright 1995-2021 Takeda Pharmaceutical Company Limited. All rights reserved.